- Abstract Number: 2464
B Cells in Anti-tRNA Synthetase Syndrome Patients Show an Activated, Interferon Responsive Signature
- Abstract Number: 1511
B-Cell Recovery in a Randomized Controlled Trial of B-Cell Depletion with Obinutuzumab for the Treatment of Proliferative Lupus Nephritis
- Abstract Number: 2010
B-FROST: Chronic OBstructive Pulmonary Disease and Vertebral FRacture of OSTeoporotic Origin: Results of a Real-life Cohort
- Abstract Number: 1042
B-line of Lung Ultrasound Reflects Different Morphological Features on Chest HRCT Between Interstitial Lung Disease Associated with Systemic Sclerosis and Myositis
- Abstract Number: 0450
Baricitinib versus TNF-inhibitors in Patients with Active Rheumatoid Arthritis After Failure of CsDMARDs: A Pragmatic, Multicenter, Real-Life Study in a Treat-to-Target Setting
- Abstract Number: 0998
Barriers and Facilitators for Osteoporosis and Sarcopenia Care for Persons Living with HIV in Peru: HIV Physician and Coordinator Perspectives
- Abstract Number: 0183
Barriers and Facilitators to Recruiting Underrepresented Participants for Clinical Trials: Insights from the Lupus Clinical Investigators Network (LuCIN)
- Abstract Number: 0172
Barriers and Strategies to Enhance Patient Research Partner Involvement in Rheumatology Research: A Systematic Literature Review
- Abstract Number: 1028
Barriers to Total Joint Arthroplasty for Patients Residing in High-Poverty Communities
- Abstract Number: 0358
Baseline Clinical Features and Biomarker Profiles of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Systemic Juvenile Idiopathic Arthritis Associated Lung Disease (SJIA-LD) Cohort
- Abstract Number: 1074
Baseline Clinical Features, but Not Shared Epitope or HLA B27, Predict Severe Outcomes for Immune Checkpoint Inhibitor-induced Inflammatory Arthritis
- Abstract Number: 1284
Baseline Data’s Role in Predicting All-cause Mortality in Chinese Rheumatoid Arthritis Patients: Findings from the China Registry of Rheumatoid Arthritis (CREDIT) Study
- Abstract Number: 2539
Baseline IL-10 Levels as a Predictive Biomarker for Achieving Clinical Response with Abatacept in ACPA+ Patients with Early RA
- Abstract Number: 0594
Baseline Innate Immunity Transcriptional Signatures Act as Predictors of Response to Immunosuppressive and Biologic Treatments in Systemic Lupus Erythematosus While Disturbances Linked to p53-signaling Define “Resistant” Disease
- Abstract Number: 0440
Baseline T Cell and B Cell-related Markers and HLA-DRB1 Shared Epitope Alleles Predict the Therapeutic Efficacy of Abatacept in Patients with Moderate to Severe Rheumatoid Arthritis
- Abstract Number: 1565
Baseline Vascular Ultrasound of Polymyalgia Rheumatica Patients at Time of Diagnosis Predicts Clinical Outcomes at 3 Months
- Abstract Number: 1562
Behcet’s Disease Coagulopathy in a Racially Diverse Patient Population
- Abstract Number: 0692
Behçet’s Disease-Associated TCR in the Eye Points to HLA Class I-Restricted Autoimmunity
- Abstract Number: 2021
Beliefs, Attitudes, and Preferences of Patients with Rheumatoid Arthritis (RA) and Concomitant Cancer with Respect to RA Therapy
- Abstract Number: 1651
Beneficial Effect of Temporary Methotrexate Interruption on B and T Cell Responses upon SARSCoV-2 Vaccination in Patients with Rheumatoid Arthritis or Psoriatic Arthritis
- Abstract Number: 0678
Benralizumab in Eosinophilic Granulomatosis with Polyangiitis
- Abstract Number: 1439
Better Drug Retention on anti-IL17A Compared to Anti-TNF Therapy Despite Its Inferior Effect on Composite Joint Indexes and Quality of Life in Patients with PsA–analysis from the Czech Biologics Registry ATTRA
- Abstract Number: 1198
Bicycling Is Not Associated with New Knee Pain or Disease Progression over 48 Months in Those with Knee Osteoarthritis: Data from the Osteoarthritis Initiative
- Abstract Number: 0525
Bimekizumab Achieved Sustained Improvements in Efficacy Outcomes in Patients with Axial Spondyloarthritis, Regardless of Prior TNF Inhibitor Treatment: Week 52 Pooled Results from Two Phase 3 Studies
- Abstract Number: 1433
Bimekizumab Impact on Core Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Domains for Patients with Psoriatic Arthritis: 52-Week Results from Four Phase 3 Studies
- Abstract Number: 2250
Bimekizumab Impact on Health-Related Quality of Life and Physical Function in Patients with Active Psoriatic Arthritis Who Were Biologic DMARD‑Naïve or Had Inadequate Response or Intolerance to TNF-α Inhibitors: 1-Year Results from Two Phase 3, Randomized Studies
- Abstract Number: 0526
Bimekizumab Improved Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: 52-Week Results from Two Phase 3 Studies
- Abstract Number: 1437
Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naïve Patients with Psoriatic Arthritis Who Were Responders at Week 16: Results from a Phase 3, Active-Reference Study
- Abstract Number: 2252
Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Patients with Psoriatic Arthritis and Inadequate Response or Intolerance to TNF-α Inhibitors Who Were Responders at Week 16: Results from a Phase 3, Randomized Study
- Abstract Number: 0523
Bimekizumab Maintained Stringent Clinical Responses Through Week 52 in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
- Abstract Number: 1441
Bimekizumab Maintenance of Response and Safety in Patients with Moderate to Severe Plaque Psoriasis: Results from the Open-label Extension Period (Weeks 48–144) of the BE RADIANT Phase 3b Trial
- Abstract Number: 0527
Bimekizumab Treatment Impact on Pain and Fatigue in Patients with Active Psoriatic Arthritis Who Were Biologic DMARD‑Naïve or Had Inadequate Response or Intolerance to TNF-α Inhibitors: 1-Year Results from Two Phase 3 Studies
- Abstract Number: 1415
Bimekizumab Treatment Impact on Work Productivity in Biologic DMARD‑Naïve and TNFi-IR Patients with Active Psoriatic Arthritis: Results up to 1 Year from Two Phase 3 Studies
- Abstract Number: 0510
Bimekizumab Treatment Improved Key Patient-Reported Symptoms of Axial Spondyloarthritis Including Spinal Pain, Fatigue, and Morning Stiffness: 52-Week Results from Two Phase 3 Studies
- Abstract Number: 2230
Bimekizumab Treatment in Patients with Active PsA and Prior Inadequate Response to TNF Inhibitors: Sustained Efficacy and Safety Results from a Phase 3 Study and Its Open-Label Extension up to 1 Year
- Abstract Number: 2255
Bimekizumab versus Secukinumab for the Treatment of Nail Psoriasis in Patients with Moderate to Severe Plaque Psoriasis: Results from the BE RADIANT Phase 3b Trial
- Abstract Number: 2249
Bimekizumab-Treated Patients with Active PsA Showed Sustained Improvement in Disease Symptoms Assessed by the PsA Impact of Disease (PsAID)-12 Questionnaire: 1-Year Results Reported from Two Phase 3 Studies
- Abstract Number: 0421
Bioinformatics Platform to Study the Genetics of Biologic DMARD Non-responders: Design and Protocol of the RA Non-responders to Treatment (RANT) Study
- Abstract Number: 0457
Biologic Disease Modifying Antirheumatic Drug Use in Immune Checkpoint Inhibitor-Treated Cancer Patients with Rheumatoid Arthritis: Utilization and Overall Survival
- Abstract Number: 1066
Biologic Drug and Anti-Drug Antibody Monitoring: All 5 TNF-Inhibitors, Infliximab, Adalimumab, Golimumab, Etanercept, Certolizumab Pegol, in 63,930 Patient Samples
- Abstract Number: 2149
Biologic IRL201805 Drives Differential Cell-contact and Metabolism Transcriptional Profiles in Monocytes from RA Patients Compared to Healthy Donors
- Abstract Number: 0391
Biologic Use Regulates the Impact of Inflammation on Ischemic Cardiovascular Risk in Rheumatoid Arthritis
- Abstract Number: 0498
Biological Therapies for Psoriasis and Psoriatic Arthritis- effects on Future Risk Development of Major Adverse Cardiovascular Events (MACE)
- Abstract Number: 1302
Biomarkers of Cardiovascular Risk in Patients with Rheumatoid Arthritis: Results from the TARGET Trial Biomarker Study
- Abstract Number: 1780
Biomarkers Predicting Structural Progression of Axial Spondyloarthritis: A Pilot Study
- Abstract Number: 2443
Blockade of OX40/OX40L Signaling Using anti-OX40L Ameliorates Systemic Lupus Erythematosus
- Abstract Number: 1693
Blood Immunophenotyping Distinguishes Three Subgroups of Lupus Nephritis Patients with Distinct Kidney Infiltrates and Interferon Signatures
- Abstract Number: 1147
Blood-Based Biomarkers of Inflammation and Tissue Remodeling Can Discriminate Between Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis and Are Associated with Hand Function
- Abstract Number: 1829
Blood-derived Extracellular Vesicles as Potential Diagnostic Biomarker in Fibromyalgia Syndrome
- Abstract Number: 1465
Blood-dominant Disease in Older-onset Lupus: A Systematic Review and Meta-analysis
- Abstract Number: 1930
Blue Digit Syndrome as the Initial Presentation of Various Diseases: A Case Series
- Abstract Number: 0570
BLyS Levels Are Elevated in Systemic Lupus Erythematosus Patients with Neuropsychiatric Manifestations
- Abstract Number: 2004
Bone Health Following Bariatric Surgery: A Single Center Quality Improvement Study
- Abstract Number: 1300
Bone Marrow Edema in MRI Is More Associated with Rapid Radiographic Progression Than Clinically Relevant Radiographic Progression
- Abstract Number: 1364
Both Low and High 25(OH)-Vitamin D Levels Increase Adverse Pregnancy Outcomes in Systemic Lupus Erythematosus
- Abstract Number: PP04
Bouncing Back: How I Found My Running Shoes Using a Rebounder for My Psoriatic Arthritis
- Abstract Number: 2258
Brain Activity Patterns and Behavioural Performance in SLE Patients During a Spatial Working Memory and Sustained Attention Task
- Abstract Number: 1824
Breakthrough COVID-19 and Severity After Vaccination Among Pregnant Persons with Rheumatic Diseases
- Abstract Number: 0225
Breakthrough SARS-Cov-2 Infection and Disease Flares in Patients with Rheumatoid Arthritis: Result from COVAD E-Survey Study
- Abstract Number: 0462
Breastfeeding Intention in Systemic Lupus Erythematosus Patients
- Abstract Number: 1176
Brepocitinib Prevents Type-I Interferon Induced Damage in Cultured Myocytes and Endothelial Cells Indicating a Potential Role in the Treatment of Dermatomyositis
- Abstract Number: 0504
Burden of Disease of Psoriatic Arthritis in Latin America: A Systemic Review of Literature
- Abstract Number: 2261
Burden of Flare and Organ Damage in Systemic Lupus Erythematosus (SLE) in the Asia Pacific Region: A Multicenter Cohort Study
- Abstract Number: 2001
Burden of Metabolic Bone Disease in Patients with IgG4-Related Disease with and Without Autoimmune Pancreatitis
- Abstract Number: 0308
Burden of Osteoarthritis Attributable to High BMI in 38 OECD Countries: A Benchmarking Analysis
ACR Convergence 2023
November 10-15, 2023. San Diego, CA.